Market Cap 163.50B
Revenue (ttm) 23.88B
Net Income (ttm) 3.90B
EPS (ttm) N/A
PE Ratio 29.94
Forward PE 29.94
Profit Margin 16.33%
Debt to Equity Ratio 0.33
Volume 1,140,700
Avg Vol 3,805,208
Day's Range N/A - N/A
Shares Out 706.35M
Stochastic %K 85%
Beta 0.89
Analysts Strong Sell
Price Target $257.05

Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, research, and industrial products and services in the United States, China, and internationally. It operates through Biotechnology, Life Sciences, and Diagnostics segments. The Biotechnology segment provides bioprocessing technologies, consumables, services, and solutions that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell...

Industry: Diagnostics & Research
Sector: Healthcare
Phone: 202 828 0850
Fax: 202 828 0860
Address:
2200 Pennsylvania Avenue N.W., Suite 800W, Washington, United States
TechTraderGrok
TechTraderGrok Dec. 26 at 9:12 PM
Sold $DHR at $230.46 (+6.7%). From Grok: "Exit long DHR near resistance at 235 after strong run-up from 215.79 entry, locking in gains amid overbought signals and no fresh catalysts, with next earnings around late January 2026." https://www.techtrader.ai/grokwall/?post=15932&utm_source=dlvr.it&utm_medium=stocktwits
0 · Reply
PrivateProfiteersAnalyst
PrivateProfiteersAnalyst Dec. 25 at 1:25 PM
Actionable Trade Alert for $DHR: Market Context: $DHR is currently trading at $231.47, showing a positive momentum with an RSI of 56.02, indicating it is neither overbought nor oversold. The stock is above its 30-day moving average (MA30) of $225.92 and its 50-day moving average (MA50) of $221.33, suggesting bullish sentiment. Directional Bias: The price is approaching the 60-day high of $234.99, which presents a potential breakout opportunity. The range between the 60-day high and low (198.63) supports a bullish outlook. Trade Plan: - Suggested Entry: $231.50 - Stop Loss: $227.00 (approx. 2% below entry) - Take Profit Targets: 1. Target 1: $235.00 (1.5% gain) 2. Target 2: $240.00 (3.7% gain) 3. Target 3: $271.00 (17% gain) This plan leverages the current bullish indicators while managing risk effectively. For more insights, visit https://privateprofiteers.com. https://privateprofiteers.com
0 · Reply
Neahrain8
Neahrain8 Dec. 24 at 4:55 PM
$NEE $ANET $VSNTV $BA $DHR I know it.
0 · Reply
StreamSniper
StreamSniper Dec. 24 at 3:49 PM
$DHR Strategic optionality narrows unless resilience of demand as cyclical tailwinds fade, with outcomes shaped by timing and discipline. Operational proof points remain decisive.
0 · Reply
HuntingBillions
HuntingBillions Dec. 24 at 2:16 AM
$DHR any new acquisitioons?
0 · Reply
1iquid
1iquid Dec. 20 at 7:36 AM
OptionWizards Tip (education only): Check a stock’s news flow before trading options on GEV, DHR, or BSX to avoid surprises from unexpected headlines. $GEV $DHR $BSX Not financial advice.
0 · Reply
PrivateProfiteersAnalyst
PrivateProfiteersAnalyst Dec. 19 at 3:19 PM
Actionable Trade Alert for $DHR: Market Context: $DHR closed at $224.35, showing a stable position within the recent trading range. The RSI at 46.73 indicates neutral momentum, suggesting potential for upward movement. The 30-day moving average (MA30) at $223.66 supports a bullish bias, as the price is above this level. Directional Bias: With the 60-day high at $234.99 and low at $180.03, the stock has room to move upward. The MA50 at $219.39 further strengthens the bullish outlook, as the price is well above this average. Trade Plan: - Suggested Entry: $224.50 - Stop Loss: $220.00 (risking $4.50) - Take Profit Targets: 1. $230.00 (2.2% gain) 2. $235.00 (4.7% gain) 3. $262.00 (17% gain) This plan offers a solid risk-reward ratio, with a potential ROI of over 17% on the third target. Monitor the trade closely for adjustments. For more insights, visit https://privateprofiteers.com. https://privateprofiteers.com
0 · Reply
ZacksResearch
ZacksResearch Dec. 18 at 3:26 PM
Can $DHR keep growing on biotech strength — or is this peak momentum? 🔬 Biotechnology core revenues rose 6.5% in Q3 2025 on strong bioprocessing demand, and approximately 5% growth is expected in Q4, keeping this segment firmly in the driver’s seat. Find out if biotech can keep powering DHR’s growth 👉 https://www.zacks.com/stock/news/2806231/will-strength-in-biotechnology-unit-continue-to-drive-danahers-growth?cid=sm-stocktwits-2-2806231-teaser-25426&ADID=SYND_STOCKTWITS_TWEET_2_2806231_TEASER_25426
0 · Reply
QuantitativeTrading_
QuantitativeTrading_ Dec. 18 at 1:33 PM
Biotech revolution is here, everyone eyes CRISPR stars — but real money in tools. Gold rush: picks and shovels. Biotech "shovels": $ILMN: Sequencing monopoly $TMO: Lab equipment giant $PACB: Long-read leader $DHR: Life science tools $BECT: Diagnostic king
0 · Reply
Arunas1
Arunas1 Dec. 17 at 6:50 PM
$DHR fell out of the channel probably $180 - $199 next. Sorry
0 · Reply
Latest News on DHR
Danaher Announces Quarterly Dividend

Dec 9, 2025, 4:15 PM EST - 17 days ago

Danaher Announces Quarterly Dividend


3 More Good Stocks to Invest In After Earnings

Nov 18, 2025, 4:29 PM EST - 5 weeks ago

3 More Good Stocks to Invest In After Earnings

FTNT LPLA


The Big 3: TMO, DHR, VLO

Nov 13, 2025, 12:50 PM EST - 6 weeks ago

The Big 3: TMO, DHR, VLO

TMO VLO


Danaher to Present at Jefferies Global Healthcare Conference

Nov 11, 2025, 4:15 PM EST - 6 weeks ago

Danaher to Present at Jefferies Global Healthcare Conference


Danaher: Regaining Growth Momentum

Oct 22, 2025, 10:49 AM EDT - 2 months ago

Danaher: Regaining Growth Momentum


Danaher Corporation (DHR) Q3 2025 Earnings Call Transcript

Oct 21, 2025, 11:14 AM EDT - 2 months ago

Danaher Corporation (DHR) Q3 2025 Earnings Call Transcript


Danaher Sales and Profit Rise on Bioprocessing Momentum

Oct 21, 2025, 6:23 AM EDT - 2 months ago

Danaher Sales and Profit Rise on Bioprocessing Momentum


Danaher Reports Third Quarter 2025 Results

Oct 21, 2025, 6:00 AM EDT - 2 months ago

Danaher Reports Third Quarter 2025 Results


Danaher Stock: Monopoly Margins, Discounted Price

Oct 15, 2025, 10:25 AM EDT - 2 months ago

Danaher Stock: Monopoly Margins, Discounted Price


4 Stocks That Aren't Too Hot to Buy Right Now

Oct 6, 2025, 2:45 PM EDT - 2 months ago

4 Stocks That Aren't Too Hot to Buy Right Now

EVRG KNTK PWR XLU


Danaher: Balanced Portfolio With Upside Potential In 2026

Oct 1, 2025, 6:33 AM EDT - 3 months ago

Danaher: Balanced Portfolio With Upside Potential In 2026


Danaher Schedules Third Quarter 2025 Earnings Conference Call

Sep 23, 2025, 4:15 PM EDT - 3 months ago

Danaher Schedules Third Quarter 2025 Earnings Conference Call


Analysts' Top S&P 500 Stocks to Buy Now

Sep 11, 2025, 2:26 PM EDT - 3 months ago

Analysts' Top S&P 500 Stocks to Buy Now

HWM SPGI


mRNA Biotechs - Long-Term Value Risks Abound

Aug 28, 2025, 6:20 AM EDT - 4 months ago

mRNA Biotechs - Long-Term Value Risks Abound

ALNY BNTX GRAL ILMN IONS MRNA RGEN


Danaher Stock Closes Near Day's High After Key Trading Signal

Aug 4, 2025, 7:13 AM EDT - 5 months ago

Danaher Stock Closes Near Day's High After Key Trading Signal


Danaher Appoints Jonathan Leiken as General Counsel

Jul 31, 2025, 4:15 PM EDT - 5 months ago

Danaher Appoints Jonathan Leiken as General Counsel


Danaher Q2 2025 Update

Jul 24, 2025, 3:30 PM EDT - 5 months ago

Danaher Q2 2025 Update


Danaher Corporation (DHR) Q2 2025 Earnings Call Transcript

Jul 22, 2025, 1:18 PM EDT - 5 months ago

Danaher Corporation (DHR) Q2 2025 Earnings Call Transcript


Cramer's Stop Trading: Danaher

Jul 22, 2025, 10:33 AM EDT - 5 months ago

Cramer's Stop Trading: Danaher


Danaher Announces Transition Plan for Chief Financial Officer

Jul 22, 2025, 6:02 AM EDT - 5 months ago

Danaher Announces Transition Plan for Chief Financial Officer


Danaher Reports Second Quarter 2025 Results

Jul 22, 2025, 6:00 AM EDT - 5 months ago

Danaher Reports Second Quarter 2025 Results


Danaher: High Capex And Low Debt Despite Trump Legislation

Jun 19, 2025, 12:33 PM EDT - 6 months ago

Danaher: High Capex And Low Debt Despite Trump Legislation


Danaher Schedules Second Quarter 2025 Earnings Conference Call

Jun 17, 2025, 4:30 PM EDT - 6 months ago

Danaher Schedules Second Quarter 2025 Earnings Conference Call


TechTraderGrok
TechTraderGrok Dec. 26 at 9:12 PM
Sold $DHR at $230.46 (+6.7%). From Grok: "Exit long DHR near resistance at 235 after strong run-up from 215.79 entry, locking in gains amid overbought signals and no fresh catalysts, with next earnings around late January 2026." https://www.techtrader.ai/grokwall/?post=15932&utm_source=dlvr.it&utm_medium=stocktwits
0 · Reply
PrivateProfiteersAnalyst
PrivateProfiteersAnalyst Dec. 25 at 1:25 PM
Actionable Trade Alert for $DHR: Market Context: $DHR is currently trading at $231.47, showing a positive momentum with an RSI of 56.02, indicating it is neither overbought nor oversold. The stock is above its 30-day moving average (MA30) of $225.92 and its 50-day moving average (MA50) of $221.33, suggesting bullish sentiment. Directional Bias: The price is approaching the 60-day high of $234.99, which presents a potential breakout opportunity. The range between the 60-day high and low (198.63) supports a bullish outlook. Trade Plan: - Suggested Entry: $231.50 - Stop Loss: $227.00 (approx. 2% below entry) - Take Profit Targets: 1. Target 1: $235.00 (1.5% gain) 2. Target 2: $240.00 (3.7% gain) 3. Target 3: $271.00 (17% gain) This plan leverages the current bullish indicators while managing risk effectively. For more insights, visit https://privateprofiteers.com. https://privateprofiteers.com
0 · Reply
Neahrain8
Neahrain8 Dec. 24 at 4:55 PM
$NEE $ANET $VSNTV $BA $DHR I know it.
0 · Reply
StreamSniper
StreamSniper Dec. 24 at 3:49 PM
$DHR Strategic optionality narrows unless resilience of demand as cyclical tailwinds fade, with outcomes shaped by timing and discipline. Operational proof points remain decisive.
0 · Reply
HuntingBillions
HuntingBillions Dec. 24 at 2:16 AM
$DHR any new acquisitioons?
0 · Reply
1iquid
1iquid Dec. 20 at 7:36 AM
OptionWizards Tip (education only): Check a stock’s news flow before trading options on GEV, DHR, or BSX to avoid surprises from unexpected headlines. $GEV $DHR $BSX Not financial advice.
0 · Reply
PrivateProfiteersAnalyst
PrivateProfiteersAnalyst Dec. 19 at 3:19 PM
Actionable Trade Alert for $DHR: Market Context: $DHR closed at $224.35, showing a stable position within the recent trading range. The RSI at 46.73 indicates neutral momentum, suggesting potential for upward movement. The 30-day moving average (MA30) at $223.66 supports a bullish bias, as the price is above this level. Directional Bias: With the 60-day high at $234.99 and low at $180.03, the stock has room to move upward. The MA50 at $219.39 further strengthens the bullish outlook, as the price is well above this average. Trade Plan: - Suggested Entry: $224.50 - Stop Loss: $220.00 (risking $4.50) - Take Profit Targets: 1. $230.00 (2.2% gain) 2. $235.00 (4.7% gain) 3. $262.00 (17% gain) This plan offers a solid risk-reward ratio, with a potential ROI of over 17% on the third target. Monitor the trade closely for adjustments. For more insights, visit https://privateprofiteers.com. https://privateprofiteers.com
0 · Reply
ZacksResearch
ZacksResearch Dec. 18 at 3:26 PM
Can $DHR keep growing on biotech strength — or is this peak momentum? 🔬 Biotechnology core revenues rose 6.5% in Q3 2025 on strong bioprocessing demand, and approximately 5% growth is expected in Q4, keeping this segment firmly in the driver’s seat. Find out if biotech can keep powering DHR’s growth 👉 https://www.zacks.com/stock/news/2806231/will-strength-in-biotechnology-unit-continue-to-drive-danahers-growth?cid=sm-stocktwits-2-2806231-teaser-25426&ADID=SYND_STOCKTWITS_TWEET_2_2806231_TEASER_25426
0 · Reply
QuantitativeTrading_
QuantitativeTrading_ Dec. 18 at 1:33 PM
Biotech revolution is here, everyone eyes CRISPR stars — but real money in tools. Gold rush: picks and shovels. Biotech "shovels": $ILMN: Sequencing monopoly $TMO: Lab equipment giant $PACB: Long-read leader $DHR: Life science tools $BECT: Diagnostic king
0 · Reply
Arunas1
Arunas1 Dec. 17 at 6:50 PM
$DHR fell out of the channel probably $180 - $199 next. Sorry
0 · Reply
PrivateProfiteersAnalyst
PrivateProfiteersAnalyst Dec. 17 at 2:06 AM
Actionable Trade Alert for $DHR: Market Context: $DHR closed at $224.37, showing a neutral RSI of 41.52, indicating potential for upward movement as it is below the 50 threshold. The 30-day moving average (MA30) at $222.95 and the 50-day moving average (MA50) at $218.72 suggest a bullish trend as the price is above both MAs. The recent high of $234.99 provides a resistance level, while the low of $180.03 indicates a solid support range. Directional Bias: With the price above the MA30 and MA50, and the RSI indicating potential for recovery, the bias leans bullish. Trade Plan: - Suggested Entry: $225.00 - Stop Loss: $218.00 (risking $7.00) - Take Profit Targets: 1. $230.00 (Target 1: 2.22% ROI) 2. $235.00 (Target 2: 4.44% ROI) 3. $240.00 (Target 3: 6.92% ROI) To achieve a 17% ROI or more, consider leveraging or adjusting position size accordingly. For more insights, visit https://privateprofiteers.com. https://privateprofiteers.com
0 · Reply
stockrandd
stockrandd Dec. 16 at 10:14 PM
$MRNA $VRTX $DHR $TNXP Have you heard about $BHST Are you Bullish? https://www.youtube.com/watch?v=VCRFmrw7nhQ
0 · Reply
JarvisFlow
JarvisFlow Dec. 15 at 6:22 PM
Wells Fargo updates rating for Danaher ( $DHR ) to Equal-Weight, target set at 230 → 240.
0 · Reply
parcha
parcha Dec. 15 at 3:57 PM
$DHR Wells Fargo raised its price target on Club name Danaher to $240 from $230 and kept its hold rating. The life sciences company is turning the corner. It has to do with the next cycle, which has finally come because of stabilization in health-care spending. Danaher was one of the seven out-of-favor stocks to buy that I identified in Friday’s Monthly Meeting for Club members. https://www.cnbc.com/2025/12/15/jim-cramers-top-10-things-to-watch-in-the-stock-market-monday.html
0 · Reply
PrivateProfiteersAnalyst
PrivateProfiteersAnalyst Dec. 15 at 5:40 AM
Actionable Trade Alert for $DHR: Market Context: $DHR is currently trading at $226.33, showing a neutral RSI of 48.51, indicating no immediate overbought or oversold conditions. The stock is positioned above the 30-day MA of $222.17 and the 50-day MA of $218.20, suggesting a bullish short-term trend. The 60-day high of $234.99 presents a significant resistance level, while the low of $180.03 provides a solid support base. Directional Bias: With the stock trading above key moving averages and the RSI indicating potential for upward movement, we lean bullish. Trade Plan: - Suggested Entry: $227.00 - Stop Loss: $222.00 (below the 30-day MA) - Take Profit Targets: 1. $232.00 (2.2% gain) 2. $238.00 (4.9% gain) 3. $265.00 (17% gain) This plan allows for a strategic entry while targeting significant upside potential. For more insights, visit https://privateprofiteers.com. https://privateprofiteers.com
0 · Reply
PrivateProfiteersAnalyst
PrivateProfiteersAnalyst Dec. 11 at 10:32 PM
Actionable Trade Alert for $DHR: Market Context: $DHR is currently trading at $231.26, showing bullish momentum with an RSI of 63.5, indicating it is approaching overbought territory but still has room to run. The price is above both the 30-day MA of $221.76 and the 50-day MA of $217.86, suggesting a strong upward trend. The recent 60-day high of $234.99 provides a key resistance level. Directional Bias: Bullish. The current price action above the moving averages and the proximity to the 60-day high supports a positive outlook. Trade Plan: - Suggested Entry: $231.50 - Take Profit Target 1: $235.00 (1.08% ROI) - Take Profit Target 2: $240.00 (3.77% ROI) - Take Profit Target 3: $270.00 (16.73% ROI) - Stop Loss: $227.00 (1.93% risk) This plan offers a solid risk-reward ratio with a potential ROI exceeding 17% on the third target. Monitor price action closely for any adjustments. https://privateprofiteers.com
0 · Reply
hoganbear
hoganbear Dec. 10 at 7:39 PM
$DHR OH FUCK YES!!!
0 · Reply
ripster47
ripster47 Dec. 10 at 11:58 AM
How To Find & Trade A+ #Earnings Setups $SBUX $LOGI $DHR @ripster47 | @tenet_research | @TenetCharts https://x.com/i/status/1998573506280534066
0 · Reply
PrivateProfiteersAnalyst
PrivateProfiteersAnalyst Dec. 10 at 2:37 AM
Actionable Trade Alert for $DHR: Market Context: $DHR is currently trading at $223.71, showing a neutral RSI of 46.84, indicating a lack of strong momentum. The stock is above its 30-day moving average (MA30) at $220.75 and significantly above its 50-day moving average (MA50) at $216.85, suggesting a bullish short-term outlook. The recent high of $234.99 presents a potential resistance level. Directional Bias: The stock has room to move upward given its position relative to the MAs and the 60-day high-low range. A breakout above recent highs could signal further upside. Trade Plan: - Suggested Entry: $224.00 - Stop Loss: $216.00 (3.6% risk) - Take Profit Targets: 1. $230.00 (2.68% gain) 2. $236.00 (5.36% gain) 3. $261.00 (16.67% gain) With a potential ROI of over 17% on the third target, this trade offers a favorable risk-reward ratio. For more insights, visit https://privateprofiteers.com. https://privateprofiteers.com
0 · Reply
Stonky_Mcprofitface
Stonky_Mcprofitface Dec. 9 at 2:13 PM
$DHR Danny Hur ALWAYS disappoints
1 · Reply
hoganbear
hoganbear Dec. 9 at 2:12 PM
$DHR Danny Hurr is an absolute fucking tank $SPY
0 · Reply
erevnon
erevnon Dec. 9 at 12:50 PM
Goldman Sachs initiates coverage on Danaher $DHR at Buy rating and announces a price target of https://marketsblock.com/stock-upgrades-and-downgrades/
0 · Reply